Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
As of close of business last night, Ginkgo Bioworks Holdings Inc’s stock clocked out at $8.12, down -2.29% from its previous closing price of $8.31. In other words, the price has decreased by -$2.29 from its previous closing price. On the day, 1.13 million shares were traded.
Ratios:
To gain a deeper understanding of DNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.88 and its Current Ratio is at 4.88. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.67.
Raymond James Downgraded its Outperform to Mkt Perform on November 14, 2023, whereas the target price for the stock was revised from $3.50 to $2.50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 13 ’25 when Che Austin bought 99 shares for $8.40 per share.
Che Austin bought 99 shares of DNA for $808 on May 12 ’25. On May 09 ’25, another insider, Che Austin, who serves as the Officer of the company, bought 99 shares for $7.97 each.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 2.00 while its Price-to-Book (P/B) ratio in mrq is 0.65.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $38.58, while it has fallen to a 52-week low of $5.00. The 50-Day Moving Average of the stock is 12.73%, while the 200-Day Moving Average is calculated to be -9.22%.
Shares Statistics:
A total of 43.08M shares are outstanding, with a floating share count of 37.41M. Insiders hold about 32.63% of the company’s shares, while institutions hold 60.11% stake in the company.
